Dyne Therapeutics Inc (NASDAQ:DYN) — Market Cap & Net Worth
Market Cap & Net Worth: Dyne Therapeutics Inc (DYN)
Dyne Therapeutics Inc (NASDAQ:DYN) has a market capitalization of $4.01 Billion ($4.01 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4056 globally and #1409 in its home market, demonstrating a 5.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dyne Therapeutics Inc's stock price $25.18 by its total outstanding shares 165313796 (165.31 Million). See Dyne Therapeutics Inc capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Dyne Therapeutics Inc Market Cap History: 2020 to 2026
Dyne Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows growth from $3.47 Billion to $4.16 Billion (0.89% CAGR).
Index Memberships
Dyne Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.16% | #95 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.01% | #463 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.23% | #62 of 263 |
Weight: Dyne Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dyne Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dyne Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DYN by Market Capitalization
Companies near Dyne Therapeutics Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Dyne Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Dyne Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Dyne Therapeutics Inc's market cap moved from $3.47 Billion to $ 4.16 Billion, with a yearly change of 0.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.16 Billion | +28.73% |
| 2025 | $3.23 Billion | -16.98% |
| 2024 | $3.89 Billion | +77.14% |
| 2023 | $2.20 Billion | +14.75% |
| 2022 | $1.92 Billion | -2.52% |
| 2021 | $1.97 Billion | -43.38% |
| 2020 | $3.47 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Dyne Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.01 Billion USD |
| MoneyControl | $4.01 Billion USD |
| MarketWatch | $4.01 Billion USD |
| marketcap.company | $4.01 Billion USD |
| Reuters | $4.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more